NF-kB p65 (3G1) Monoclonal Antibody

$Lane 1: MCF-7; Lane 2: Hela lysate probed with NF-kB p65 (3G1) Monoclonal Antibody, unconjugated (bsm-52305R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: MCF-7; Lane 2: Hela lysate probed with NF-kB p65 (3G1) Monoclonal Antibody, unconjugated (bsm-52305R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

Flow cytometric analysis of HeLa cells with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$IF(ICC) staining with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:100 in A549 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human lung cancer tissue incubated with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human lung cancer tissue incubated with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with NF-kB p65 (3G1) Monoclonal Antibody (bsm-52305R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Lane 1:Human MCF-7 cell lysates; Lane 2: Human MOLT-4 cell lysates; Lane 3: Human A549 cell lysates; Lane 4: Human Jurkat cell lysates; Lane 5: Mouse RAW264.7 cell lysates; Lane 6: Mouse NIH\/3T3 cell lysates; Lane 7: Mouse Spleen lysates; Lane 8: Mouse Lung lysates probed with NF-kB p65 Monoclonal Antibody, Unconjugated (bsm-52305R ) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1:Human MCF-7 cell lysates; Lane 2: Human MOLT-4 cell lysates; Lane 3: Human A549 cell lysates; Lane 4: Human Jurkat cell lysates; Lane 5: Mouse RAW264.7 cell lysates; Lane 6: Mouse NIH\/3T3 cell lysates; Lane 7: Mouse Spleen lysates; Lane 8: Mouse Lung lysates probed with NF-kB p65 Monoclonal Antibody, Unconjugated (bsm-52305R ) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse
Zebrafish

Overview
Catalog #	bsm-52305R
Product Name	NF-kB p65 (3G1) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human, Mouse, Zebrafish
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human NF-kB p65 between 500 to the C-terminus
Clonality	Monoclonal
Clone #	3G1
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	5970
Swiss Prot	Q04206
Synonyms	Transcription factor p65, Nuclear factor NF-kappa-B p65 subunit, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, RELA, NFKB3
Background	NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p15, NFKB1/p5, REL and NFKB2/p52 and the heterodimeric p65-p5 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p5 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC

Applications

Reactivity

Search our catalog of hundreds of thousands of products